Breaking News

PAREXEL Acquires ATLAS

July 2, 2014

Expands footprint in Turkey, the Middle East, and North Africa

PAREXEL has acquired ATLAS Medical Services, a provider of clinical research services in Turkey, the Middle East, and North Africa. ATLAS provides services for all phases of clinical development, along with study planning and feasibility, site selection, data management, and medical writing, and has therapeutic expertise in oncology, hematology, endocrinology, cardiovascular, anesthesiology, infectious diseases and the central nervous system. The firm also provides regulatory services to support product registration.
 
ATLAS, headquartered in Istanbul, has 35 employees, with additional offices in Ankara and Izmir. Its 2013 revenues were approximately $4 million.
 
Josef von Rickenbach, chairman and chief executive officer of PAREXEL said, "The acquisition of ATLAS strengthens PAREXEL's presence in Turkey, the Middle East and North Africa. These markets are of increasing importance to our clients who are looking for market access and a broad spectrum of patient populations for clinical trials. In addition, ATLAS has been a trusted business partner to PAREXEL for many years, and their infrastructure and staff are already aligned with our processes and operations. By fully integrating ATLAS into PAREXEL's global operations, we will enhance our ability to help clients more quickly achieve their goals of bringing important therapies to patients not only in Turkey, the Middle East, and North Africa, but also throughout the rest of the world."
 

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research